## EW: Edwards Lifesciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.4% below STRENGTH zone (3.0-6.0%); PEG 4.78 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($82.74)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Edwards wins FDA nod for Sapien M3 mitral valve, marking first transseptal transcatheter therapy**
- Source: MassDevice | 20251223T143440 | Bullish | Relevance: 100%
- Edwards Lifesciences has received FDA approval for its Sapien M3 mitral valve replacement system, the first transcatheter mitral regurgitation therapy to use a transseptal approach. This approval came ahead of schedule and allows the device to treat patients with symptomatic moderate-to-severe or severe MR who are unsuitable for surgery or TEER therapy. The Sapien M3 system, which builds on the proven Sapien platform, also treats symptomatic mitral valve dysfunction associated with mitral annular calcification.

**2. New catheter-based heart valve offers option for patients unfit for surgery**
- Source: Stock Titan | 20251223T140159 | Bullish | Relevance: 100%
- Edwards Lifesciences has received FDA approval for its SAPIEN M3 mitral valve replacement system, marking it as the first transcatheter therapy utilizing a transseptal approach for mitral regurgitation. This system provides a new treatment option for patients deemed unsuitable for traditional surgery or other repair therapies. The SAPIEN M3 offers a fully percutaneous mitral valve replacement, which has shown significant elimination of mitral regurgitation and improved patient symptoms and quality of life in clinical trials.

**3. Edwards Lifesciences’ SAPIEN M3 becomes first FDA-approved mitral valve system**
- Source: Investing.com | 20251223T142340 | Bullish | Relevance: 100%
- Edwards Lifesciences has received FDA approval for its SAPIEN M3 mitral valve replacement system, the first transcatheter therapy using a transseptal approach for mitral regurgitation. This approval covers patients unsuitable for surgery or transcatheter edge-to-edge repair and those with mitral valve dysfunction associated with mitral annular calcification. The company is trading near its 52-week high, reflecting investor optimism, and analysts have recently upgraded its stock ratings.

**4. OFI Invest Asset Management Raises Stock Holdings in Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251223T114258 | Somewhat-Bullish | Relevance: 100%
- OFI Invest Asset Management significantly increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 46.3% in the third quarter of 2025, now owning 497,068 shares valued at $38.66 million. This increase follows strong Q3 earnings for Edwards Lifesciences, which surpassed analyst expectations for both EPS and revenue. Despite insider selling activity, analysts maintain a "Moderate Buy" rating for the company with an average price target of $93.95.

**5. How JP Morgan’s Upgrade and 2026 Conference Spotlight Will Impact Edwards Lifesciences (EW) Investors**
- Source: Simply Wall Street | 20251222T033246 | Somewhat-Bullish | Relevance: 100%
- Edwards Lifesciences (EW) will participate in the 44th Annual J.P. Morgan Healthcare Conference in January 2026, coinciding with a recent JP Morgan analyst upgrade to Overweight with a $100 price target. This increased analyst confidence highlights the market's close attention to Edwards' cardiovascular innovation roadmap. While the conference and upgrade bring positive attention to products like early TAVR and EVOQUE, key challenges remain around regulatory progress, tariffs, acquisition dilution, and international competition.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 11, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | JP Morgan | $100 | $90 | +11% |
| 2025-12-17 | Canaccord Genui | $87 | $89 | -2% |
| 2025-12-16 | Baird | $87 | $88 | -1% |
| 2025-12-11 | Citigroup | $101 | $96 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | JP Morgan | up | Overweight |
| 2025-12-17 | Canaccord Genui | main | Hold |
| 2025-12-16 | Baird | main | Neutral |
| 2025-12-11 | Citigroup | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 12 ($3.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.5%)
- Blackrock Inc.: 9.4% (-2.4%)
- JPMORGAN CHASE & CO: 8.6% (+87.2%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.6% (+4.9%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. Valuation stretched: PEG 4.8x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 11 raises (avg +5%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 4.78 signals overvaluation risk, limited margin of safety. Forward P/E 30.0x stretched relative to 11% growth. Quality metrics strong (margin 23%). Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.30). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $50.6B |
| Beta | 0.97 |
| 52W Range | $65.94 - $87.89 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.78 |
| Forward P/E | 30.0 |
| Current P/E | 33.4 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 3.4% to 0.4% (-3.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.6pp (needs >3.0% for momentum thesis). MRS_5 (-0.8%) diverging from MRS_10 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.36% (CS: 76) | Neutral |
| RSI_14 | 57.9 | Neutral |
| MACD Histogram | 0.03 | Bullish |
| vs SMA20 | 1.013x | Above |
| vs SMA50 | 1.041x | Above |
| vs SMA200 | 1.112x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $86.22
- **Stop Loss:** $82.74 (4.0% risk)
- **Target:** $89.70 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 344
- **Position Value:** $29,659.68
- **Portfolio %:** 29.66%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-11 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.67 | +12.6% |
| 2025Q2 | $0.62 | $0.67 | +7.6% |
| 2025Q1 | $0.60 | $0.64 | +7.5% |
| 2024Q4 | $0.55 | $0.59 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*